In situ Antibiotic-Loaded Copper Tannic Acid Coordination Nanospheres Targeting Biofilms for the Treatment of Chronic Osteomyelitis
International Journal of Nanomedicine · 2025
DOI: 10.2147/ijn.s548765 ↗At a glance
Journal article in International Journal of Nanomedicine, 2025. Written by Ziming Ren and 3 co-authors. Institution: Department of Traumatic Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China. Major MEDLINE topics: Biofilms, Tannins, Osteomyelitis, Anti-Bacterial Agents. Cited 5 times so far (Crossref); 65 references. The full text is freely available (open access, CC BY-NC 3.0).
Abstract (original language)
Purpose
The formation of biofilms hinders direct contact between antibiotics and bacteria, reducing the efficacy of antibiotic therapy and presenting a substantial obstacle to the treatment of chronic osteomyelitis. To address this problem, we successfully constructed a chemically and structurally robust vancomycin-copper-tannic acid (Van@CuTA) antibiotic sustained-release system via a simple synthetic method, to target bacteria and inhibit biofilm formation.
Methods
Tannic acid (TA), copper ions (Cu2+), and vancomycin hydrochloride (Van) were mixed and stirred at a low temperature to afford Van@CuTA nanospheres. Their antibacterial activity was evaluated against methicillin-resistant S. aureus (MRSA) using the Oxford cup method and live/dead bacterial staining. Their anti-biofilm activity was assessed via FE-SEM observations. Cell viability was assessed via MTT assay and osteogenic activity was detected via Western blotting (WB) and alkaline phosphatase (ALP) staining after co-culture with MG-63 cells. In vivo tibia-induced osteomyelitis model in rabbits was conducted to further validate the efficacy of Van@CuTA in treating osteomyelitis.
Results
The developed nanospheres exhibited drug release properties, with TA being released from the carrier and inhibiting the formation of bacterial biofilms. In vivo experiments demonstrated inhibition of MRSA biofilm formation through the encapsulation of TA within fibrin and its sustained release, followed by the sequential release of Van and Cu2⁺ to directly eradicate MRSA. Moreover, Van@CuTA effectively promoted cell proliferation and bone formation. Van@CuTA is a multifunctional system that integrates biofilm targeting, drug release, antimicrobial activity, and cuproptosis-like bacterial death.
Conclusion
This study offers a novel and promising strategy for the development of antimicrobial agents to combat MRSA-induced chronic osteomyelitis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Traumatic Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
- Department of Infectious Diseases & Anhui Center for Surveillance of Bacterial Resistance, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
- Anhui Province Key Laboratory of Infectious Diseases & Institute of Bacterial Resistance & Institute of Infectious Diseases, Anhui Medical University, Hefei, Anhui, People's Republic of China.
ORCID profiles: Ziming Ren, Yanyan Liu
Cite
APA
Ren, Z., Zhang, Y., Liu, Y., & Wang, G. (2025). In situ Antibiotic-Loaded Copper Tannic Acid Coordination Nanospheres Targeting Biofilms for the Treatment of Chronic Osteomyelitis. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s548765
Vancouver
Ren Z, Zhang Y, Liu Y, Wang G. In situ Antibiotic-Loaded Copper Tannic Acid Coordination Nanospheres Targeting Biofilms for the Treatment of Chronic Osteomyelitis. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s548765
BibTeX
@article{Ren2025,
author = {Ren, Ziming and Zhang, Yuelei and Liu, Yanyan and Wang, Gang},
title = {In situ Antibiotic-Loaded Copper Tannic Acid Coordination Nanospheres Targeting Biofilms for the Treatment of Chronic Osteomyelitis},
journal = {International Journal of Nanomedicine},
year = {2025},
doi = {10.2147/ijn.s548765}
}
EUVIMED